Image
WTS Database
The subject of interest is:
waterpipe, water-pipe, nargile, narghile, arguileh, arguile, shisha, sheesha, chichi, hubble bubble, hubbly bubbly, goza, hookah, bong
| Title | Pub Year | Author Sort descending | SearchLink |
|---|---|---|---|
| Alcohol, marijuana, and tobacco use patterns among youth in Canada | 2008 | Division of Preventive Oncology, Cancer Care Ontario, 620 University Avenue, Toronto, ON, Canada M5G 2L7. scott.leatherdale@cancercare.on.ca | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Cancer causes & control : CCC
Periodical, Abbrev.
Cancer Causes Control
Pub Date Free Form
May
Volume
19
Issue
4
Start Page
361
Other Pages
369
Notes
JID: 9100846; 2007/05/14 [received]; 2007/11/13 [accepted]; 2007/12/06 [aheadofprint]; ppublish
Place of Publication
Netherlands
ISSN/ISBN
0957-5243; 0957-5243
Accession Number
PMID: 18058247
Language
eng
SubFile
Journal Article; Research Support, Non-U.S. Gov't; IM
DOI
10.1007/s10552-007-9095-4 [doi]
Output Language
Unknown(0)
PMID
18058247
Abstract
The authors characterized changes in the prevalence of alcohol, tobacco, and marijuana use over time, and examined age of onset, co-morbid use and sociodemographic factors associated with ever using alcohol, tobacco, or marijuana in a nationally representative sample of Canadian youth. Data were collected from students in grades 7-9 as part of the Canadian Youth Smoking Survey (n = 19,018 in 2002; n = 29,243 in 2004). Descriptive analyses examined age of onset, co-morbid substance use and changes over time. Logistic regression models were used to examine factors associated with ever trying alcohol, tobacco, or marijuana with the 2004 data. Alcohol was the most prevalent substance used by youth and it was also the only substance which exhibited increased rates of use between 2002 and 2004. Co-morbid substance use was common, and it was rare to find youth who had used marijuana or tobacco without also having tried alcohol. As expected, youth who had poorer school performance were more likely to drink and smoke marijuana or tobacco, as were youth with more disposable income. Such timely and relevant data are important for guiding future policy, programming, and surveillance activities.
Descriptors
Adolescent, Adolescent Behavior, Age of Onset, Alcohol Drinking/epidemiology/prevention & control/trends, Canada/epidemiology, Child, Child Behavior, Comorbidity, Demography, Female, Humans, Logistic Models, Male, Marijuana Smoking/epidemiology/prevention & control/trends, Prevalence, Risk Factors, Sampling Studies, Smoking/epidemiology/prevention & control/trends, Students, Tobacco
Links
Book Title
Database
Publisher
Data Source
Authors
Leatherdale,S. T., Hammond,D., Ahmed,R.
Original/Translated Title
URL
Date of Electronic
20071206
PMCID
Editors
|
|||
| Interventions for smokeless tobacco use cessation | 2015 | Division of Primary Care Internal Medicine, Mayo Clinic, 200 1st Street Southwest, Rochester, Minnesota, USA, 55905. | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The Cochrane database of systematic reviews
Periodical, Abbrev.
Cochrane Database Syst.Rev.
Pub Date Free Form
26-Oct
Volume
(10):CD004306. doi
Issue
10
Start Page
CD004306
Other Pages
Notes
LR: 20160602; JID: 100909747; 0 (Benzazepines); 0 (Chewing Gum); 0 (Nicotinic Agonists); 0 (Quinoxalines); 01ZG3TPX31 (Bupropion); 6M3C89ZY6R (Nicotine); W6HS99O8ZO (Varenicline); epublish
Place of Publication
England
ISSN/ISBN
1469-493X; 1361-6137
Accession Number
PMID: 26501380
Language
eng
SubFile
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1002/14651858.CD004306.pub5 [doi]
Output Language
Unknown(0)
PMID
26501380
Abstract
BACKGROUND: Use of smokeless tobacco (ST) can lead to tobacco dependence and long-term use can lead to health problems including periodontal disease, cancer, and cerebrovascular and cardiovascular disease. OBJECTIVES: To assess the effects of behavioural and pharmacologic interventions for the treatment of ST use. SEARCH METHODS: We searched the Cochrane Tobacco Addiction Group specialised register in June 2015. SELECTION CRITERIA: Randomized trials of behavioural or pharmacological interventions to help users of ST to quit with follow-up of at least six months. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by the Cochrane Collaboration. We summarised outcomes as risk ratios (RRs). For subgroups of trials with similar types of intervention and without substantial statistical heterogeneity, we estimated pooled effects using a Mantel-Haenszel fixed-effect method. MAIN RESULTS: We identified 34 trials that met the inclusion criteria, of which nine were new for this update, representing over 16,000 participants. There was moderate quality evidence from two studies suggesting that varenicline increases ST abstinence rates (risk ratio [RR] 1.34, 95% confidence interval (CI) 1.08 to 1.68, 507 participants). Pooled results from two trials of bupropion did not detect a benefit of treatment at six months or longer (RR 0.89, 95% CI 0.54 to 1.44, 293 participants) but the confidence interval was wide. Neither nicotine patch (five trials, RR 1.13, 95% CI 0.93 to 1.37, 1083 participants) nor nicotine gum (two trials, RR 0.99, 95% CI 0.68 to 1.43, 310 participants) increased abstinence. Pooling five studies of nicotine lozenges did increase tobacco abstinence (RR 1.36, 95% CI 1.17 to 1.59, 1529 participants) but confidence in this estimate is low as the result is sensitive to the exclusion of three trials which did not use a placebo control.Statistical heterogeneity was evident among the 17 trials of behavioural interventions: eight of them reported statistically and clinically significant benefits; six suggested benefit but with wide CIs and no statistical significance; and three had similar intervention and control quit rates and relatively narrow CIs. Heterogeneity was not explained by study design (individual or cluster randomization), whether participants were selected for interest in quitting, or specific intervention components. In a post hoc subgroup analysis, trials of behavioural interventions incorporating telephone support, with or without oral examination and feedback, were associated with larger effect sizes, but oral examination and feedback alone were not associated with benefit.In one trial an interactive website increased abstinence more than a static website. One trial comparing immediate cessation using nicotine patch versus a reduction approach using either nicotine lozenge or brand switching showed greater success for the abrupt cessation group. AUTHORS' CONCLUSIONS: Varenicline, nicotine lozenges and behavioural interventions may help ST users to quit. Confidence in results for nicotine lozenges is limited. Confidence in the size of effect from behavioural interventions is limited because the components of behavioural interventions that contribute to their impact are not clear.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Ebbert,J.O., Elrashidi,M.Y., Stead,L.F.
Original/Translated Title
URL
Date of Electronic
20151026
PMCID
Editors
|
|||
| Pharmacological interventions for promoting smoking cessation during pregnancy | 2015 | Division of Primary Care, University of Nottingham, D1411, Medical School, Queen's Medical Centre, Nottingham, UK, NG7 2UH. | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The Cochrane database of systematic reviews
Periodical, Abbrev.
Cochrane Database Syst.Rev.
Pub Date Free Form
22-Dec
Volume
(12):CD010078. doi
Issue
12
Start Page
CD010078
Other Pages
Notes
LR: 20160602; GR: Department of Health/United Kingdom; JID: 100909747; 0 (Nicotinic Agonists); 01ZG3TPX31 (Bupropion); W6HS99O8ZO (Varenicline); epublish
Place of Publication
England
ISSN/ISBN
1469-493X; 1361-6137
Accession Number
PMID: 26690977
Language
eng
SubFile
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1002/14651858.CD010078.pub2 [doi]
Output Language
Unknown(0)
PMID
26690977
Abstract
BACKGROUND: Smoking in pregnancy is a public health problem. When used by non-pregnant smokers, pharmacotherapies (nicotine replacement therapy (NRT), bupropion and varenicline) are effective for smoking cessation, however, their efficacy and safety in pregnancy remains unknown. Electronic Nicotine Delivery Systems (ENDS), or e-cigarettes, are becoming widely used but their efficacy and safety when used for smoking cessation in pregnancy are also unknown. OBJECTIVES: To determine the efficacy and safety of smoking cessation pharmacotherapies (including NRT, varenicline and bupropion), other medications, or ENDS when used for smoking cessation in pregnancy. SEARCH METHODS: We searched the Pregnancy and Childbirth Group's Trials Register (11 July 2015), checked references of retrieved studies, and contacted authors. SELECTION CRITERIA: Randomised controlled trials (RCTs) conducted in pregnant women with designs that permit the independent effects of any type of pharmacotherapy or ENDS on smoking cessation to be ascertained were eligible for inclusion.The following RCT designs are included.Placebo-RCTs: any form of NRT, other pharmacotherapy, or ENDS, with or without behavioural support/cognitive behaviour therapy (CBT), or brief advice, compared with an identical placebo and behavioural support of similar intensity.RCTs providing a comparison between i) any form of NRT, other pharmacotherapy, or ENDS added to behavioural support/CBT, or brief advice and ii) behavioural support of similar (ideally identical) intensity.Parallel- or cluster-randomised trials were eligible for inclusion. Quasi-randomised, cross-over and within-participant designs were not, due to the potential biases associated with these designs. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias and also independently extracted data and cross checked individual outcomes of this process to ensure accuracy. The primary efficacy outcome was smoking cessation in later pregnancy (in all but one trial, at or around delivery); safety was assessed by 11 outcomes (principally birth outcomes) that indicated neonatal and infant well-being; and we also collated data on adherence with trial treatments. MAIN RESULTS: This review includes a total of nine trials which enrolled 2210 pregnant smokers: eight trials of NRT and one trial of bupropion as adjuncts to behavioural support/CBT. The risk of bias was generally low across trials with virtually all domains of the 'Risk of bias' assessment tool being satisfied for the majority of studies. We found no trials investigating varenicline or ENDS. Compared to placebo and non-placebo controls, there was a difference in smoking rates observed in later pregnancy favouring use of NRT (risk ratio (RR) 1.41, 95% confidence interval (CI) 1.03 to 1.93, eight studies, 2199 women). However, subgroup analysis of placebo-RCTs provided a lower RR in favour of NRT (RR 1.28, 95% CI 0.99 to 1.66, five studies, 1926 women), whereas within the two non-placebo RCTs there was a strong positive effect of NRT, (RR 8.51, 95% CI 2.05 to 35.28, three studies, 273 women; P value for random-effects subgroup interaction test = 0.01). There were no differences between NRT and control groups in rates of miscarriage, stillbirth, premature birth, birthweight, low birthweight, admissions to neonatal intensive care, caesarean section, congenital abnormalities or neonatal death. Compared to placebo group infants, at two years of age, infants born to women who had been randomised to NRT had higher rates of 'survival without developmental impairment' (one trial). Generally, adherence with trial NRT regimens was low. Non-serious side effects observed with NRT included headache, nausea and local reactions (e.g. skin irritation from patches or foul taste from gum), but these data could not be pooled. AUTHORS' CONCLUSIONS: NRT used in pregnancy for smoking cessation increases smoking cessation rates measured in late
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Coleman,T., Chamberlain,C., Davey,M.A., Cooper,S.E., Leonardi-Bee,J.
Original/Translated Title
URL
Date of Electronic
20151222
PMCID
Editors
|
|||
| Pharmacological interventions for promoting smoking cessation during pregnancy | 2012 | Division of Primary Care, University of Nottingham, Nottingham, UK. tim.coleman@nottingham.ac.uk. | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The Cochrane database of systematic reviews
Periodical, Abbrev.
Cochrane Database Syst.Rev.
Pub Date Free Form
12-Sep
Volume
(9):CD010078. doi
Issue
9
Start Page
CD010078
Other Pages
Notes
LR: 20160602; GR: Department of Health/United Kingdom; JID: 100909747; UIN: Cochrane Database Syst Rev. 2015;(12):CD010078. PMID: 26690977; epublish
Place of Publication
England
ISSN/ISBN
1469-493X; 1361-6137
Accession Number
PMID: 22972148
Language
eng
SubFile
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1002/14651858.CD010078 [doi]
Output Language
Unknown(0)
PMID
22972148
Abstract
BACKGROUND: Smoking in pregnancy is a substantial public health problem. When used by non-pregnant smokers, pharmacotherapies [nicotine replacement therapy (NRT), bupropion and varenicline] are effective treatments for smoking cessation, however, their efficacy and safety in pregnancy remains unknown. OBJECTIVES: To determine the efficacy and safety of smoking cessation pharmacotherapies, including NRT, varenicline and bupropion (or any other medications) when used to support smoking cessation in pregnancy. SEARCH METHODS: We searched the Pregnancy and Childbirth Group's Trials Register (5 March 2012), checked references of retrieved studies and contacted authors in the field. SELECTION CRITERIA: Randomised controlled trials (RCTs) with designs that permit the independent effects of any type of NRT (e.g. patch, gum etc.) or any other pharmacotherapy on smoking cessation to be ascertained were eligible for inclusion. Trials must provide very similar (ideally identical) levels of behavioural support or cognitive behaviour therapy (CBT) to participants in active drug and comparator trial arms.The following RCT designs are considered acceptable.Placebo RCTs: any form of NRT or other pharmacotherapy, with or without behavioural support/CBT, or brief advice compared with placebo NRT and additional support of similar intensity.RCTs providing a comparison between i) behavioural support/CBT or brief advice and ii) any form of NRT or other pharmacotherapy added to behavioural support of similar (ideally identical) intensity.Parallel- or cluster-randomised design trials are eligible for inclusion. However, quasi-randomised, cross-over and within-participant designs are not eligible for inclusion due to the potential biases associated with these designs. DATA COLLECTION AND ANALYSIS: Two review authors independently assessed trials for inclusion and risk of bias and extracted data. Two assessors independently extracted data and cross checked individual outcomes of this process to ensure accuracy. The primary efficacy outcome was smoking cessation in later pregnancy (in all but one trial, at or around delivery); safety was assessed by seven birth outcomes that indicated neonatal well being and we also collated data on adherence. MAIN RESULTS: Six trials of NRT enrolling 1745 pregnant smokers were included; we found no trials of varenicline or bupropion. No statistically significant difference was seen for smoking cessation in later pregnancy after using NRT as compared to control (risk ratio (RR) 1.33, 95% confidence interval (CI) 0.93 to 1.91, six studies, 1745 women). Subgroup analysis comparing placebo-RCTs with those which did not use placebos found that efficacy estimates for cessation varied with trial design (placebo RCTs, RR 1.20, 95% CI 0.93 to 1.56, four studies, 1524 women; non-placebo RCTs, RR 7.81, 95% CI 1.51 to 40.35, two studies, 221 women; P value for random-effects subgroup interaction test = 0.03). There were no statistically significant differences in rates of miscarriage, stillbirth, premature birth, birthweight, low birthweight, admissions to neonatal intensive care or neonatal death between NRT or control groups. AUTHORS' CONCLUSIONS: Nicotine replacement therapy is the only pharmacotherapy for smoking cessation that has been tested in RCTs conducted in pregnancy. There is insufficient evidence to determine whether or not NRT is effective or safe when used to promote smoking cessation in pregnancy or to determine whether or not using NRT has positive or negative impacts on birth outcomes. Further research evidence of efficacy and safety is needed, ideally from placebo-controlled RCTs that investigate higher doses of NRT than were tested in the included studies.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Coleman,T., Chamberlain,C., Davey,M.A., Cooper,S.E., Leonardi-Bee,J.
Original/Translated Title
URL
Date of Electronic
20120912
PMCID
Editors
|
|||
| Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: a community clinic-based case-control study | 2009 | Division of Public Health Sciences, Department of Epidemiology Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
The American Journal of Gastroenterology
Periodical, Abbrev.
Am.J.Gastroenterol.
Pub Date Free Form
Apr
Volume
104
Issue
4
Start Page
834
Other Pages
842
Notes
LR: 20141210; GR: K05 CA124911/CA/NCI NIH HHS/United States; GR: K05 CA124911/CA/NCI NIH HHS/United States; GR: K05 CA124911-02/CA/NCI NIH HHS/United States; GR: R01 CA072866/CA/NCI NIH HHS/United States; GR: R01 CA072866-04/CA/NCI NIH HHS/United States;
Place of Publication
United States
ISSN/ISBN
1572-0241; 0002-9270
Accession Number
PMID: 19319131
Language
eng
SubFile
Comparative Study; Journal Article; Research Support, N.I.H., Extramural; IM
DOI
10.1038/ajg.2009.137 [doi]
Output Language
Unknown(0)
PMID
19319131
Abstract
OBJECTIVES: Our aim was to measure the relative risks of Barrett's esophagus (BE) associated with demographic factors, measures of adiposity, and smoking among patients with gastroesophageal reflux disease (GERD). METHODS: Patients newly diagnosed with specialized intestinal metaplasia (SIM) (n=197) were compared with patients with GERD (n=418) in a community clinic-based case-control study. Case subgroups included those with any visible columnar epithelium (VBE) (n=97), and those with a long segment (>or=2 cm) of columnar epithelium (LSBE) (n=54). RESULTS: Risks increased with older age (adjusted odds ratio (aOR) per decade for SIM=1.3, 95% confidence interval (CI)=1.1-1.5; VBE aOR=1.4, CI=1.1-1.6; LSBE aOR=1.5, CI=1.2-1.9), male gender (SIM aOR=1.5, CI=1.1-2.2; VBE aOR=2.7, CI=1.6-4.5; LSBE aOR=3.9, CI=1.9-8.1), and possibly Asian race. Increased risk of BE was observed with high waist-to-hip ratio (WHR, male high: >or=0.9, female high: >or=0.8) (SIM aOR=1.3, CI=0.9-2.1; VBE aOR=1.9, CI=1.0-3.5; LSBE aOR=4.1, CI=1.5-11.4). These associations were independent of body mass index (BMI) for the VBE and LSBE case groups but not for SIM, which was the only case group in which BMI was a significant risk factor. Ever having smoked cigarettes increased risk similarly for all case groups (SIM aOR=1.8, CI=1.2-2.6; VBE aOR=1.6, CI=1.0-2.6; LSBE aOR=2.6, CI=1.3-4.9), although a dose-response relationship was not detected for duration or intensity of smoking. CONCLUSIONS: Older age, male gender, and history of smoking increased risk of SIM and BE among GERD patients independent of other risk factors for BE. Central adiposity was most strongly related to risk of VBE and LSBE. These results may be useful in the development of risk profiles for screening GERD patients.
Descriptors
Adult, Age Distribution, Aged, Aged, 80 and over, Barrett Esophagus/epidemiology/etiology/pathology, Body Mass Index, Confidence Intervals, Female, Gastroesophageal Reflux/complications/epidemiology/pathology, Humans, Intestinal Mucosa/pathology, Male, Middle Aged, Odds Ratio, Precancerous Conditions, Retrospective Studies, Risk Factors, Sex Distribution, Smoking/adverse effects/epidemiology, Washington/epidemiology, Young Adult
Links
Book Title
Database
Publisher
Data Source
Authors
Edelstein,Z. R., Bronner,M. P., Rosen,S. N., Vaughan,T. L.
Original/Translated Title
URL
Date of Electronic
20090324
PMCID
PMC2714477
Editors
|
|||
| Protecting the world from secondhand tobacco smoke exposure: where do we stand and where do we go from here? | 2013 | Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis, St. Louis, MO 63110, USA. barnoyaj@wudosis.wustl.edu | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Periodical, Abbrev.
Nicotine Tob.Res.
Pub Date Free Form
Apr
Volume
15
Issue
4
Start Page
789
Other Pages
804
Notes
LR: 20150222; GR: HHSN261201100185P/PHS HHS/United States; GR: R03CA153959/CA/NCI NIH HHS/United States; JID: 9815751; 0 (Tobacco Smoke Pollution); OID: NLM: PMC3601911; 2012/10/15 [aheadofprint]; ppublish
Place of Publication
England
ISSN/ISBN
1469-994X; 1462-2203
Accession Number
PMID: 23072872
Language
eng
SubFile
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review; IM
DOI
10.1093/ntr/nts200 [doi]
Output Language
Unknown(0)
PMID
23072872
Abstract
INTRODUCTION: Article 8 of the Framework Convention on Tobacco Control mandates all signatory countries to "protect citizens from exposure to tobacco smoke in workplaces, public transport and indoor public places." Even though there has been great progress in the implementation of Article 8, still most of the world population remains exposed to secondhand smoke (SHS). In this article, we sought to summarize the research that supports Article 8, where do we stand, and current research gaps and future directions. DISCUSSION: Secondhand smoke is an established cause of heart disease and several types of cancer. Additional research is needed to reach final conclusions for diseases where evidence is only suggestive of causality. The only solution to SHS exposure in public places is banning smoking indoors. Research on the gaming industry and nightclubs, particularly in developing countries, needs to be disseminated to support their inclusion in smoke-free laws. Aside from indoor bans, additional research is needed for outdoor and multiunit housing bans and in support of measures that protect children and other vulnerable populations. The impact of smoke-free laws on other health outcomes, besides heart disease and respiratory outcomes, is another area where further research is needed. Thirdhand smoke assessment and health effects are also likely to be a topic of further research. As new tobacco products emerge, evaluating SHS exposure and effects will be vital. CONCLUSIONS: Furthering research in support of Article 8 can contribute to reach the final goal of protecting everyone from SHS exposure.
Descriptors
Links
Book Title
Database
Publisher
Data Source
Authors
Barnoya,J., Navas-Acien,A.
Original/Translated Title
URL
Date of Electronic
20121015
PMCID
PMC3601911
Editors
|
|||
| Acceptance and Commitment Therapy and nicotine patch for smokers with bipolar disorder: preliminary evaluation of in-person and telephone-delivered treatment | 2015 | Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Group Health Research Institute, Seattle, WA, USA.; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.; Department of | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Bipolar disorders
Periodical, Abbrev.
Bipolar Disord.
Pub Date Free Form
Aug
Volume
17
Issue
5
Start Page
560
Other Pages
566
Notes
LR: 20160801; CI: (c) 2015; GR: K23 DA026517/DA/NIDA NIH HHS/United States; GR: K23DA026517/DA/NIDA NIH HHS/United States; JID: 100883596; NIHMS677651; OID: NLM: NIHMS677651; OID: NLM: PMC4526426; OTO: NOTNLM; 2014/11/26 [received]; 2015/01/23 [accepted];
Place of Publication
Denmark
ISSN/ISBN
1399-5618; 1398-5647
Accession Number
PMID: 25912192
Language
eng
SubFile
Clinical Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; IM
DOI
10.1111/bdi.12300 [doi]
Output Language
Unknown(0)
PMID
25912192
Abstract
OBJECTIVES: People with bipolar disorder are two to three times more likely to smoke and 50% less likely to quit than the general population. New treatments are needed to improve smoking cessation outcomes in this group. The study aim was to develop and pilot test a novel cessation intervention for smokers with bipolar disorder using Acceptance and Commitment Therapy (ACT) combined with nicotine patches. METHODS: The ten-session ACT intervention was initially evaluated as in-person, individual counseling (n = 10), then as telephone-delivered counseling (n = 6). Participants were adult smokers with no more than mild current symptoms of bipolar disorder. RESULTS: For the in-person protocol, end-of-treatment outcomes were: 80% retention, 40% of participants with carbon monoxide (CO)-verified seven-day point prevalence abstinence (PPA), 90% satisfied with treatment, 8.3 of ten sessions attended, and 54% increase in acceptance of cravings to smoke (i.e., ACT's theory-based change process) from baseline. The seven-day PPA at one-month follow-up was 30%. For the telephone protocol, end-of-treatment outcomes were: 67% retention, 33% reporting seven-day PPA, 100% satisfied with treatment, 6.7 of ten treatment calls completed, and 55% increase in acceptance from baseline. At one-month follow-up, seven-day PPA was 17%. The proportion of treatment completers who used at least 80% of the nicotine patches was 62.5% for the in-person protocol and 0% for the telephone protocol. CONCLUSIONS: Both in-person and telephone-delivered ACT were feasible. Despite low adherence to nicotine patches, the intervention showed preliminary evidence of facilitating quitting and impacting ACT's change mechanism. A randomized, controlled trial of this targeted ACT intervention is now needed.
Descriptors
Links
Book Title
Database
Publisher
John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Data Source
Authors
Heffner,J.L., McClure,J.B., Mull,K.E., Anthenelli,R.M., Bricker,J.B.
Original/Translated Title
URL
Date of Electronic
20150425
PMCID
PMC4526426
Editors
|
|||
| Randomized trial of telephone-delivered acceptance and commitment therapy versus cognitive behavioral therapy for smoking cessation: a pilot study | 2014 | Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA; Department of Psychology, University of Washington, Seattle, WA; jbricker@fhcrc.org.; Alere Wellbeing, Seattle, WA.; Alere Wellbeing, Seattle, WA.; Division of Public | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Periodical, Abbrev.
Nicotine Tob.Res.
Pub Date Free Form
Nov
Volume
16
Issue
11
Start Page
1446
Other Pages
1454
Notes
LR: 20151101; CI: (c) The Author 2014; GR: K23 DA026517/DA/NIDA NIH HHS/United States; GR: K23DA026517/DA/NIDA NIH HHS/United States; GR: R01 CA151251/CA/NCI NIH HHS/United States; GR: R01 CA166646/CA/NCI NIH HHS/United States; GR: R01CA151251/CA/NCI NIH
Place of Publication
England
ISSN/ISBN
1469-994X; 1462-2203
Accession Number
PMID: 24935757
Language
eng
SubFile
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; IM
DOI
10.1093/ntr/ntu102 [doi]
Output Language
Unknown(0)
PMID
24935757
Abstract
OBJECTIVE: We conducted a pilot randomized trial of telephone-delivered acceptance and commitment therapy (ACT) versus cognitive behavioral therapy (CBT) for smoking cessation. METHOD: Participants were 121 uninsured South Carolina State Quitline callers who were adult smokers (at least 10 cigarettes/day) and who wanted to quit within the next 30 days. Participants were randomized to 5 sessions of either ACT or CBT telephone counseling and were offered 2 weeks of nicotine replacement therapy (NRT). RESULTS: ACT participants completed more calls than CBT participants (M = 3.25 in ACT vs. 2.23 in CBT; p = .001). Regarding satisfaction, 100% of ACT participants reported their treatment was useful for quitting smoking (vs. 87% for CBT; p = .03), and 97% of ACT participants would recommend their treatment to a friend (vs. 83% for CBT; p = .06). On the primary outcome of intent-to-treat 30-day point prevalence abstinence at 6 months postrandomization, the quit rates were 31% in ACT versus 22% in CBT (odds ratio [OR] = 1.5, 95% confidence interval [CI] = 0.7-3.4). Among participants depressed at baseline (n = 47), the quit rates were 33% in ACT versus 13% in CBT (OR = 1.2, 95% CI = 1.0-1.6). Consistent with ACT's theory, among participants scoring low on acceptance of cravings at baseline (n = 57), the quit rates were 37% in ACT versus 10% in CBT (OR = 5.3, 95% CI = 1.3-22.0). CONCLUSIONS: ACT is feasible to deliver by phone, is highly acceptable to quitline callers, and shows highly promising quit rates compared with standard CBT quitline counseling. As results were limited by the pilot design (e.g., small sample), a full-scale efficacy trial is now needed.
Descriptors
Links
Book Title
Database
Publisher
. Published by Oxford University Press on behalf of the Society for Research on Nicotine and Tobacco
Data Source
Authors
Bricker,J.B., Bush,T., Zbikowski,S.M., Mercer,L.D., Heffner,J.L.
Original/Translated Title
URL
Date of Electronic
20140616
PMCID
PMC4200023
Editors
|
|||
| A newly identified susceptibility locus near FOXP1 modifies the association of gastroesophageal reflux with Barrett's esophagus | 2015 | Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington. Department of Biostatistics, University of Washington, School of Public Health, Seattle, Washington. jdai@fredhutch.org tvaughan@u.washington.edu.; Division o | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Periodical, Abbrev.
Cancer Epidemiol.Biomarkers Prev.
Pub Date Free Form
Nov
Volume
24
Issue
11
Start Page
1739
Other Pages
1747
Notes
LR: 20160715; CI: (c)2015; GR: K05 CA124911/CA/NCI NIH HHS/United States; GR: K05CA124911/CA/NCI NIH HHS/United States; GR: K24 DK100548/DK/NIDDK NIH HHS/United States; GR: P01 CA053996/CA/NCI NIH HHS/United States; GR: P01 CA091955/CA/NCI NIH HHS/United
Place of Publication
United States
ISSN/ISBN
1538-7755; 1055-9965
Accession Number
PMID: 26377193
Language
eng
SubFile
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; IM
DOI
10.1158/1055-9965.EPI-15-0507 [doi]
Output Language
Unknown(0)
PMID
26377193
Abstract
BACKGROUND: Important risk factors for esophageal adenocarcinoma and its precursor, Barrett's esophagus, include gastroesophageal reflux disease, obesity, and cigarette smoking. Recently, genome-wide association studies have identified seven germline single-nucleotide polymorphisms (SNP) that are associated with risk of Barrett's esophagus and esophageal adenocarcinoma. Whether these genetic susceptibility loci modify previously identified exposure-disease associations is unclear. METHODS: We analyzed exposure and genotype data from the BEACON Consortium discovery phase GWAS, which included 1,516 esophageal adenocarcinoma case patients, 2,416 Barrett's esophagus case patients, and 2,187 control participants. We examined the seven newly identified susceptibility SNPs for interactions with body mass index, smoking status, and report of weekly heartburn or reflux. Logistic regression models were used to estimate ORs for these risk factors stratified by SNP genotype, separately for Barrett's esophagus and esophageal adenocarcinoma. RESULTS: The odds ratio for Barrett's esophagus associated with at least weekly heartburn or reflux varied significantly with the presence of at least one minor allele of rs2687201 (nominal P = 0.0005, FDR = 0.042). ORs (95% CIs) for weekly heartburn or reflux among participants with 0, 1, or 2 minor alleles of rs2687201 were 6.17 (4.91-7.56), 3.56 (2.85-4.44), and 3.97 (2.47-6.37), respectively. No statistically significant interactions were observed for smoking status and body mass index. CONCLUSION: Reflux symptoms are more strongly associated with Barrett's esophagus risk among persons homozygous for the major allele of rs2687201, which lies approximately 75 kb downstream of the transcription factor gene FOXP1. IMPACT: The novel gene-exposure interaction discovered in this study provides new insights into the etiology of esophageal adenocarcinoma.
Descriptors
Links
Book Title
Database
Publisher
American Association for Cancer Research
Data Source
Authors
Dai,J.Y., de Dieu Tapsoba,J., Buas,M.F., Onstad,L.E., Levine,D.M., Risch,H.A., Chow,W.H., Bernstein,L., Ye,W., Lagergren,J., Bird,N.C., Corley,D.A., Shaheen,N.J., Wu,A.H., Reid,B.J., Hardie,L.J., Whiteman,D.C., Vaughan,T.L.
Original/Translated Title
URL
Date of Electronic
20150916
PMCID
PMC4816532
Editors
|
|||
| The growing epidemic of water pipe smoking: health effects and future needs | 2014 | Division of Pulmonary and Critical Care Medicine, Faculty of Medicine, American University of Beirut and Medical Center, Beirut, Lebanon.; Faculty of Medicine, American University of Beirut, Beirut, Lebanon.; Division of Pulmonary and Critical Care Medici | Read more... |
|
Source Type
Print(0)
Ref Type
Journal Article
Periodical, Full
Respiratory medicine
Periodical, Abbrev.
Respir.Med.
Pub Date Free Form
Sep
Volume
108
Issue
9
Start Page
1241
Other Pages
1253
Notes
LR: 20151119; CI: Copyright (c) 2014; JID: 8908438; 0 (Carcinogens); 0 (Hazardous Substances); 6M3C89ZY6R (Nicotine); OTO: NOTNLM; 2014/03/06 [received]; 2014/07/01 [revised]; 2014/07/29 [accepted]; 2014/08/07 [aheadofprint]; ppublish
Place of Publication
England
ISSN/ISBN
1532-3064; 0954-6111
Accession Number
PMID: 25130679
Language
eng
SubFile
Journal Article; Review; IM
DOI
10.1016/j.rmed.2014.07.014 [doi]
Output Language
Unknown(0)
PMID
25130679
Abstract
Water pipe smoking (WPS), an old method of tobacco smoking, is re-gaining widespread popularity all over the world and among various populations. Smoking machine studies have shown that the water pipe (WP) mainstream smoke (MSS) contains a wide array of chemical substances, many of which are highly toxic and carcinogenic for humans. The concentrations of some substances exceed those present in MSS of cigarettes. Despite being of low grade, current evidence indicates that WPS is associated with different adverse health effects, not only on the respiratory system but also on the cardiovascular, hematological, and reproductive systems, including pregnancy outcomes. In addition, association between WPS and malignancies, such as lung, oral and nasopharyngeal cancer, has been suggested in different studies and systematic reviews. Despite its long standing history, WPS research still harbors a lot of deficiencies. The magnitude of toxicants and carcinogen exposures, effects on human health, as well as the addiction and dependence potentials associated with WPS need to be studied in well-designed prospective trials. Unfortunately, many of the tobacco control and clean indoor policies have exempted water pipes. World wide awareness among the public, smokers, and policymakers about the potential health effects of WPS is urgently required. Furthermore, stringent policies and laws that control and ban WPS in public places, similar to those applied on cigarettes smoking need to be implemented.
Descriptors
Links
Book Title
Database
Publisher
Elsevier Ltd
Data Source
Authors
Bou Fakhreddine,H.M., Kanj,A.N., Kanj,N.A.
Original/Translated Title
URL
Date of Electronic
20140807
PMCID
Editors
|
|||